EGFR and non-small cell lung carcinoma: A phase II study showed that osimertinib (160 mg/day) achieved an objective response rate (ORR) of 27.5% and a DCR of 82.5% in EGFR T790M-positive NSCLC with BM/LM, the mPFS was 5.7 months, and the common AEs included decreased appetite, diarrhea, and skin rash, most grade 1 or 2 levels (19).